CRBP biotech catalysts & pipeline

CORBUS PHARMACEUTICALS HOLDINGS INC · Data as of 2026-09-08

Upcoming catalysts

CRB-701 — Regulatory decision

H2 2026

Registrational pathway update following FDA engagement

CRB-913 — Topline data

Sep 2026

• Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in obesity and on track to report data in September 2026

Source filing

CRB-701 — Topline data

Q1 2027

• Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027 to support potential further registration-enabling trials in the front line.

Source filing

Explore the free biotech catalyst calendar